Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,154 | 0,160 | 06.09. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
26.08. | Cytophage Technologies Ltd: Cytophage gets Health Canada OK for OvaPhage, PhageFend | 1 | Stockwatch | ||
25.08. | Cytophage Technologies erhält von Health Canada die Validierung für die Produkte OvaPhage und PhageFend zur Verwendung im Bereich Lebensmittelsicherheit | 326 | IR-WORLD | - Cytophage
erhält von Health Canada Unbedenklichkeitsbescheinigungen für zwei seiner innovativen Bakteriophagenprodukte
- Regulatorischer Meilenstein beschleunigt... ► Artikel lesen | |
25.08. | Cytophage Technologies Ltd.: Cytophage Secures Health Canada Validation for OvaPhage and PhageFend Products for use in Food Safety | 5 | TheNewswire | ||
01.08. | Cytophage Technologies Ltd: Cytophage Technologies appoints Wellner as chairman | 1 | Stockwatch | ||
01.08. | Cytophage Technologies Ltd.: Cytophage Welcomes New Chairman Thomas Wellner and Announces Grant of Options and RSUs | 1 | TheNewswire | ||
CYTOPHAGE TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
29.07. | Cytophage Technologies Ltd: Cytophage's AviPhage matches antibiotics in EU study | 1 | Stockwatch | ||
28.07. | Cytophage Technologies Ltd.: Cytophage Technologies Reports Successful E. Coli Containment in EU Pilot Study for AviPhage | 1 | TheNewswire | ||
28.07. | Cytophage Technologies meldet erfolgreiche Eindämmung von E. coli-Bakterien in EU-Pilotstudie für AviPhage | 292 | IR-WORLD | Folgestudie läuft - Ergebnisse werden für das dritte Quartal erwartet
Winnipeg, den 28. Juli 2025 - Cytophage Technologies ("Cytophage" oder "das Unternehmen") (TSXV:CYTO / FWB:70G)... ► Artikel lesen | |
21.06. | Cytophage Technologies Ltd: Cytophage 7.75-million-share private placement | 1 | Stockwatch | ||
11.06. | Cytophage Technologies Ltd.: Cytophage Announces Closing of Upsized Non-Brokered Private Placement | 2 | TheNewswire | ||
11.06. | Cytophage Technologies Ltd: Cytophage closes $1.55-million private placement | 1 | Stockwatch | ||
03.06. | Cytophage Technologies Ltd: Cytophage nominates Wellner as new director | 1 | Stockwatch | ||
03.06. | Cytophage Technologies Ltd.: Cytophage Announces Mailing of Annual and Special Meeting Materials with Board Nominees | 1 | TheNewswire | ||
30.05. | Cytophage Technologies Ltd: Cytophage increases private placement to $1.55-million | 1 | Stockwatch | ||
30.05. | Cytophage Technologies Ltd.: Cytophage Announces Upsizing of its Non-Brokered Private Placement | 2 | TheNewswire | ||
14.05. | Cytophage Technologies Ltd: Cytophage arranges $1-million private placement | 2 | Stockwatch | ||
14.05. | Cytophage Technologies Ltd.: Cytophage Announces Non-Brokered Private Placement | 1 | TheNewswire | ||
09.05. | Cytophage Technologies Ltd: Cytophage receives Cdn gov't OK for enterococci trials | 2 | Stockwatch | ||
08.05. | Cytophage Technologies erhält von der kanadischen Regierung die "New Substance Notification"-Genehmigung zur Durchführung von Enterokokken-Phagentherapie-Studien | 511 | IR-WORLD | Genehmigung der kanadischen Regierung für humantherapeutischen Phagen ermöglicht einen entscheidenden ersten Schritt in Richtung klinische Anwendung und ebnet den
Weg zu einem kommerziellen Multiphagen-Produkt
... ► Artikel lesen | |
08.05. | Cytophage Technologies Ltd. Secures Government of Canada New Substance Notification Approval to Facilitate Enterococcus Phage Therapy Trials | 4 | TheNewswire |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 96,05 | +0,05 % | BioNTech-Aktie springt hoch: "Meilenstein" im Kampf gegen Krebs | Die deutsche Biotech-Gesellschaft BioNTech kommt der ersten Marktzulassung für ein Krebsmedikament wieder ein Stück näher. Am Freitag berichten die Mainzer und der chinesische Partner DualityBio über... ► Artikel lesen | |
QIAGEN | 40,390 | +0,44 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Dies schrieb Analyst Tycho Peterson in seinem am Freitag... ► Artikel lesen | |
NUVALENT | 80,89 | +1,53 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
DYNE THERAPEUTICS | 14,220 | +7,40 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen | |
EVOTEC | 5,856 | +2,70 % | Evotec-Aktie: Ist das ein wichtiges Signal? | Die Evotec-Aktie bewegt sich weiterhin auf einem sehr niedrigen Niveau; am Montag verbessert sie sich aktuell um +1,5% und steht bei rund 6,10 €. Was bei dem deutschen Biotech-Unternehmen fehlt, sind... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 4,610 | +1,99 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 50,38 | +3,81 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
BEAM THERAPEUTICS | 20,890 | +12,68 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 25,980 | +9,16 % | Summit Therapeutics stock maintains Buy rating at H.C. Wainwright on ivonescimab progress | ||
MINERALYS THERAPEUTICS | 34,750 | +4,92 % | Mineralys reports positive subgroup data for hypertension drug | ||
VERA THERAPEUTICS | 24,220 | +10,59 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 4, 2025, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
CG ONCOLOGY | 33,105 | +7,00 % | CG Oncology Inc.: CG Oncology Completes Enrollment in PIVOT-006 | - Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) -- One of the largest randomized phase 3 studies in this patient population will encompass... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 59,42 | -0,50 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update | Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the... ► Artikel lesen | |
ARS PHARMACEUTICALS | 10,090 | -5,61 % | Roth/MKM initiates ARS Pharmaceuticals stock with Buy rating on neffy potential | ||
ARCUTIS BIOTHERAPEUTICS | 17,200 | +6,11 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen |